Electromed (AMEX:ELMD) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $0.13 by 30.77 percent. This is a 41.67 percent increase over earnings of $0.12 per share from the same period last year. The company reported quarterly sales of $13.87 million which beat the analyst consensus estimate of $13.80 million by 0.51 percent. This is a 14.94 percent increase over sales of $12.07 million the same period last year.
Gainers Cogent Biosciences (NASDAQ:COGT) stock increased by 64.0% to $8.96 during Wednesday's regular session. The company's market cap stands at $771.2 million. Larimar Therapeutics (NASDAQ:LRMR) shares increased by 45.53% to $12.72. The company's market cap stands at $558.4 million. BioXcel Therapeutics (NASDAQ:BTAI) stock rose 35.2% to $3.33. The company's market cap stands at $101.0 million. Greenwich LifeSciences (NASDAQ:GLSI) stock moved upwards by 31.26% to $10.91. The company's market cap stands at $140.1 million. Electromed (AMEX:ELMD) stock rose 22.61% to $12.43. The market value of their outstanding shares is at $106.6 million. As per the news, the Q2 earnings report came out
Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that effective as of September 11, 2024, its board of directors authorized the repurchase of up to $5.0 million of Electromed common stock. The new authorization follows the exhaustion of Electromed's previous share repurchase authorization in the fourth quarter of fiscal 2024, as previously reported. The timing and amount of share repurchases pursuant to the authorization, if any, will be determined by management based on market conditions and other considerations. Repurchases may be made from time to time on the open market at prevailing market prices, in privately negotiate
Record Q4 and full year financial results Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ("Q4 FY 2024") and full year ("FY 2024") ended June 30, 2024. Q4 FY 2024 Financial Highlights Net revenues increased 9.0% to a record $14.8 million in Q4 FY 2024, from $13.6 million in the fourth quarter of the prior fiscal year. Gross margin was 76.2% of revenue, compared to 76.8% in the fourth quarter of the prior fiscal year. Operating income increased by 56.3% to a record $2.3 million or 15.7% of revenue, compared with $1.5 million or 11.0% of revenue in the fourth quarter of the p
Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2024 fourth quarter ended June 30, 2024, on August 27, 2024 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (877) 407-0789 (Domestic) or (201) 689-8562 (International). The live conference call webcast will be accessible in the Investor Relations section of Electromed's website and directly via the following link: Electromed Q4 Fiscal 2024 Webcast F
4 - Electromed, Inc. (0001488917) (Issuer)
4 - Electromed, Inc. (0001488917) (Issuer)
4 - Electromed, Inc. (0001488917) (Issuer)
Record Q4 and full year financial results Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ("Q4 FY 2024") and full year ("FY 2024") ended June 30, 2024. Q4 FY 2024 Financial Highlights Net revenues increased 9.0% to a record $14.8 million in Q4 FY 2024, from $13.6 million in the fourth quarter of the prior fiscal year. Gross margin was 76.2% of revenue, compared to 76.8% in the fourth quarter of the prior fiscal year. Operating income increased by 56.3% to a record $2.3 million or 15.7% of revenue, compared with $1.5 million or 11.0% of revenue in the fourth quarter of the p
Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2024 fourth quarter ended June 30, 2024, on August 27, 2024 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (877) 407-0789 (Domestic) or (201) 689-8562 (International). The live conference call webcast will be accessible in the Investor Relations section of Electromed's website and directly via the following link: Electromed Q4 Fiscal 2024 Webcast F
Growth initiatives drive record revenue Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ended March 31, 2024 ("Q3 FY 2024"). Q3 FY 2024 Financial Highlights Net revenues increased 15% to a record $13.9 million in Q3 FY 2024, from $12.1 million in the third quarter of the prior fiscal year. Gross margins were 75% of net revenues in the third quarters of both the current and prior fiscal years. Operating income increased by 54% to $1,841,000 or 13% of revenue, compared with $1,196,000 or 10% of revenue in the third quarter of the prior fiscal year. Net income was $1,493,00
4 - Electromed, Inc. (0001488917) (Issuer)
4 - Electromed, Inc. (0001488917) (Issuer)
4 - Electromed, Inc. (0001488917) (Issuer)
SC 13G/A - Electromed, Inc. (0001488917) (Subject)
SC 13G/A - Electromed, Inc. (0001488917) (Subject)
SC 13D/A - Electromed, Inc. (0001488917) (Subject)
Healthcare Executive Brings More Than 30 Years of Executive Experience and Commercial Success to Electromed Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced the appointment of Jim Cunniff as its new President and Chief Executive Officer (CEO), effective July 1, 2023. Mr. Cunniff will also join Electromed's Board of Directors. "We are pleased to announce the appointment of Jim Cunniff as president and CEO," said Lee Jones, Chair of the Board. "Jim is a proven executive with deep experience driving growth and profitability through excellence in products and services that benefit patients and support care teams. "As Kathle
Accomplished medical device leader to fill key strategic role Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that its Board of Directors has appointed Brad Nagel as the Company's Chief Financial Officer, effective November 14, 2022. Mr. Nagel brings to Electromed over fifteen years of financial leadership and strategic planning experience with Fortune 500 companies. Most recently, Mr. Nagel held the position of Divisional Chief Financial Officer of Global Lung Health and Visualization at Medtronic and was a key contributor in driving the unit's revenue growth. In that role, he served as the primary busine
Key appointment will guide the Company's strategic growth initiatives Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced the appointment of Christopher Holland as Chief Commercial Officer. Mr. Holland, an accomplished sales and marketing veteran, brings 30 years of experience in driving commercial growth in the Medical Technology market to Electromed. Prior to joining Electromed, Holland was the Vice President of Commercialization at Prosomnus Sleep Technologies, Inc., a Medical Device manufacturer of a mandibular advancement device for sleep apnea where he led new product introduction and revenue-growth init
8-K - Electromed, Inc. (0001488917) (Filer)
10-K - Electromed, Inc. (0001488917) (Filer)
8-K - Electromed, Inc. (0001488917) (Filer)